Marker Therapeutics, Inc. has announced a collaboration with Cellipont Bioservices to support the cGMP manufacturing of MT-601, its lead Multi-Antigen Recognizing (MAR)-T cell therapy, currently in ...
The CEO of ModeX Therapeutics discusses MDX2003, a groundbreaking tetraspecific therapy that promises enhanced efficacy and ...
Clinical study from Baylor College of Medicine demonstrates a favorable safety profile and up to 84.6% disease control rate in patients with ...
Marker Therapeutics (MRKR) is a clinical-stage immuno-oncology Company with the worldwide exclusive license of Multi-Antigen Targeted T cells, a ...
News Medical on MSN
UBC researchers crack code to grow helper t cells from stem cells
For the first time, researchers at the University of British Columbia have demonstrated how to reliably produce an important type of human immune cell-known as helper T cells-from stem cells in a ...
Chimeric antigen receptor (CAR) T-cell therapies have transformed cancer and autoimmune disease treatment. Modified CAR proteins equip T cells with the ability to identify and eliminate cancer cells ...
CellVoyant, an AI-first biotech based in Bristol UK, today launches FateView™, the first online predictive cell analytics platform designed to help cell-based therapeutic drug developers reduce costs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback